PRA Health Sciences posted another quarter of revenue growth but is narrowing its full-year sales projection.
Charles River Laboratories returned to revenue growth on a wave of dealmaking, lifting its full-year guidance in response.
Chinese CRO WuXi PharmaTech extended its run of quarterly growth on the eve of a shareholder vote that could take the company private in a multibillion-dollar deal.
Lux Ventures and a joint venture between Novartis and Qualcomm are investing $6.5 million into Science 37, an upstart company that promises to make clinical trials more efficient by uniting stakeholders.
Parexel International, in the process of shedding about 850 jobs, saw its net income dip in the fiscal first quarter, dimming its expectations for the full year.
INC Research is ticking up its revenue expectations for 2015 after turning in another quarter of sales growth, counting on its expanded operation to keep contracts rolling in.
Irish-headquartered CRO Icon kept its streak of quarterly revenue growth running, posting a 1.8% year-over-year increase in sales.
CRO PRA Health Sciences upsized one of its European outposts, investing in bioanalytical services to bolster its clinical research operations in the region.
CRO giant Quintiles posted another $1 billion revenue quarter on the way to a record year, but the company is narrowing its sales projections over ongoing foreign exchange issues.
BioClinica is changing how it does business with other CROs, the company said, responding to client demand and rolling out a new partnering program.
SRI International's CRO division signed a deal with the National Institutes of Health that could bring in up to $100 million over 5 years, agreeing to help develop therapies designed to treat the effects of radiation exposure.
India's Syngene, the recently IPO'd CRO division of Biocon, kept up its years-long run of growth with a 28% revenue boost in the second quarter of its fiscal year.
Quintiles signed a deal with healthcare information giant IMS Health to pair its own clinical development expertise with its partner's huge trove of real-world data, planning to use anonymized patient information to steer drug trials.
Quintiles, the world's largest CRO, is promoting a new chief operating officer from within and bringing on an external chief financial officer as the company rolls toward a record revenue year.
Evotec's CRO division signed a deal with the Beyond Batten Disease Foundation to help discover new potential treatments for the rare, fatal nervous disorder.
PRA Health Sciences added biotech veteran Linda Grais to its board of directors, broadening its managerial suite as it works to grow around the globe.
Contract drug developer Frontage Laboratories is expanding its business to include agrochemical testing, adding capacity in hopes of lengthening its client roster.
Cel-Sci, at work on a Phase III cancer treatment, has signed up to borrow up to $5 million as it pursues a $50 million lawsuit against former CRO partner inVentiv Health.
Contract drug developer Aesica wants to become its clients' sole point of contact among their many vendors, pitching an all-encompassing service offering.
INC Research added a new tool for early-stage safety studies, bringing in a new technology the company says will make Phase I cardiac trials more efficient.